The UK’s National Institute for Health and Care Excellence has recommended AbbVie’s Skyrizi (risankisumab) for treating moderate to severe plaque psoriasis under certain conditions.

The institute has endorsed the interleukin-23 (IL-23) antagonist for treating the disease in adults if they haven’t responded to or cannot take other treatments like ciclosporin, methotrexate and phototherapy. The drug regimen should be ended at 16 weeks if the patient hasn’t responded sufficiently to the treatment, NICE said.

Skyrizi received the FDA’s green light in April for treating moderate to severe plaque psoriasis based on positive results from clinical trials.